Strategy

AKLRD identifies secondary metabolites of plant origin whose safety and efficacy have already been established in their original form

AKLRD identifies secondary metabolites of plant origin whose safety and efficacy have already been established in their original form.

AKLRD then synthesizes and formulates these active molecule(s), exposes them to rigorous preclinical testing and progresses them through standard pharmaceutical clinical development.

This innovative approach substantially lowers the risk, and associated costs, of unexpected adverse events and lack of efficacy.

It is AKLRD’s intention to access global markets via partner(s) following proof of concept.